Floatz logo

Exenatide

Metabolic Dysfunction-Associated Steatotic Liver Disease

Fudan Universityprotein_peptidePhase 4 / ApprovedDormant
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
64/ 100
Competitive Position
89/ 100

Competitive context

131 Active assets in the Metabolic Dysfunction-Associated Steatotic Liver Disease cohort.

Asset / SponsorPhaseRating
Dapagliflozin
Post Graduate Institute of Medical Education and Research, Chandigarh
Phase 4BBB
Metformin
Xiqiao Zhou
Phase 4BBB
Pioglitazone
Badr University
Phase 4BBB
Empagliflozin
Justin Ryder
Phase 4BBB
Tirzepatide
Regeneron Pharmaceuticals
Phase 3BBB

View all 50 →

Same molecule, other indications

Exenatide is also rated in:

type 2 diabetes mellitusActive
BBB
Indicative · Phase 4
78 / 100
View asset →
prediabetes syndromeDormant
BBB
Indicative · Phase 4
76 / 100
View asset →
polycystic ovary syndromeDormant
BB
Indicative · Phase 4
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →